A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.

Authors :: Kuruvilla J
Rushton C
Villa D
Aslam M
Prica A
Abdel Samad N
Doucet S
Dudebout J
Fleury I
Fraser G
Larouche JF
Shafey M
Skrabek P
Skamene T
Morin RD
Alcaide M
Ben-Neriah S
Lee D
Winch C
Shepherd LE
Scott DW
Crump M
Chen BE
Hay AE
Source :: British journal of haematology [Br J Haematol] 2024 Sep 12. Date of Electronic Publication: 2024 Sep 12.
Publication Year :: 2024
Publisher :: Ahead of Print
Abstract: In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.<br /> (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)

Full Text Access

Tools